Weighing the Three Preferred First-Line Options Against Mrs. Chen's Goals of Care

Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.

Osimertinib monotherapy is convenient and scan-based follow-up is typically every 3 months, which is attractive for her teaching schedule, and it is chemotherapy-free. However, Dr. Gumbleton notes this option gives up on the goal of maximal expected survival, which may not be the best fit for her.

Amivantamab plus lazertinib has good survival outcomes and is chemotherapy-free, which keeps her chemo-free preference intact. The trade-off is more clinic visits; in the longer term, the minimum frequency is roughly monthly.

Osimertinib plus chemotherapy has improved survival over osimertinib alone but involves the most clinic visits: chemotherapy every 3 weeks, with pemetrexed maintenance continuing every 3 weeks as long as the patient is willing and able. Dr. Gumbleton notes this option does not meet her chemo-free preference and is the most burdensome given her travel distance.

He also raises a patient-specific chemotherapy risk: As a teacher exposed to children who are frequently ill, Mrs. Chen may have a higher-than-average risk of febrile illness and potentially neutropenic fever on chemotherapy, which could increase the risk of hospitalization compared with an average patient.

In the next episode, “Clinical Significance of the TP53 Co-Mutation,” Dr. Gumbleton explains why this high-risk biology shifts the decision away from single-agent osimertinib.